INVESTIGADORES
LANUSSE Carlos Edmundo
artículos
Título:
Understanding triclabendazole resistance. Experimental Molecular Pathology,
Autor/es:
BRENNAN GP,; FAIRWEATHER I,; TRUDGETT A,; HOEY E,; MCCOY, M,; MCFERRAN N,; RYAN L,; LANUSSE C,; MOTTIER L,; ALVAREZ L, .; SOLANA H,; VIRKEL G,; BROPHY PM
Revista:
EXPERIMENTAL MOLECULAR PATHOLOGY
Editorial:
Elsevier Inc.
Referencias:
Año: 2007 p. 104 - 109
Resumen:
Abstract
Triclabendazole (TCBZ) has been the drug of choice to treat liver fluke infections in
livestock for >20 years, due to its high activity against both adult and juvenile flukes.
More recently, it has been used successfully to treat human cases of fascioliasis.
Resistance to TCBZ first appeared in the field in Australia in the mid-1990s. Since
then, resistance has been reported from a number of countries throughout Europe:
Ireland, Scotland, Wales, Spain and The Netherlands. The heavy reliance on a single
drug puts treatment strategies for fascioliasis at risk. Should resistance develop
further, the prospect is an alarming one.
This review will present an overview of progress in understanding the mechanism of
resistance to TCBZ, examining possible changes in the target molecule, in drug
influx/efflux mechanisms and in the metabolism of TCBZ by the fluke. The review
will also consider ways to deal with resistance, covering drug-oriented options such
as: the use of alternative drugs, drug combinations and the search for new compounds.
Key words; Triclabendazole; Fasciola hepatica; resistance; ß-tubulin isotype;
molecular modeling; P-glycoprotein; drug metabolism; proteomics.
molecular modeling; P-glycoprotein; drug metabolism; proteomics.
Fasciola hepatica; resistance; ß-tubulin isotype;
molecular modeling; P-glycoprotein; drug metabolism; proteomics.